Orbis Medicines
Last verified 2026-06-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $28.1Mattributed |
|---|---|
| Latest round | seed, $28.1M, 2024-02-01attributed |
| Founded | 2022 |
| Headquarters | Copenhagen, Denmark |
| Industry | bio |
| Stage | seed |
| Website | orbismedicines.com |
Orbis Medicines develops oral macrocycle drugs via its nGen platform, designing compounds called nCycles to turn injectable biologics into pills. It serves patients on biologic therapies and pharma partners seeking oral alternatives. A single design-make-test cycle generates up to 100,000 target-specific nCycles.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-02-01 | seed | $28.1M | undisclosed |
Detected tech stack
@sentry/browser, adobe fonts, afterpay, hsts, moment 0, parallax.js, squarespace, squarespace commerce, stimulus, typekit, web-vitals
Provenance
| Fact | Status | Basis |
|---|---|---|
| Seed, $28.1M | attributed | sifted named as publisher. No document URL on file. |
| Total raised $28.1M | attributed | sifted named as publisher. No document URL on file. |
| Company existence | self-reported | orbismedicines.com, read 2026-06-07 |
| Description | self-reported | orbismedicines.com, read 2026-06-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.